Heart failure & cardiomyopathiesCohort study
Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision
- Prospective cohort study
Authors' conclusion
The study underscores that higher TCF on 68Ga-FAPI-04 PET/CT imaging might be a correlated factor of worse clinical outcome in newly diagnosed AL-CA, and this metric seems to be a molecular imaging tool complementary to 18F-florbetapir imaging.
Study context
- Population
- Patients with confirmed AL cardiac amyloidosis (AL-CA)
- Participants
- 38 patients
- Outcome
- Association of 18F-florbetapir and 68Ga-FAPI-04 PET/CT metrics with overall survival
Main finding
As reported in the abstract
Overall survival · median follow-up 24.8 months
Deaths
13
Observational data: associations, not effects.
Further findings
Amyloid deposition and cardiac fibroblast activation
- Cardiac fibroblast activation
- 86.8% (33 of 38)
- Amyloid deposition in all patients
Correlations of positron emission tomography (PET)/computed tomography (CT) metrics
- Cardiac amyloid burden correlated with Mayo stage and several echocardiography metrics
- P < 0.05
- CFV correlated with NT-proBNP level
- P < 0.05
Original publication
Molecular Stratification of Light-Chain Cardiac Amyloidosis With 18F-Florbetapir and 68Ga-FAPI-04 for Enhanced Prognostic Precision. JACC Cardiovasc Imaging. Published 8 January 2025. doi:10.1016/j.jcmg.2024.10.001
Summarised from the published abstract; every number is checked against it